Shots:
- Gilead has exercised its options to 3 programs in Arcus’s portfolio, including both anti-TIGIT molecules, domvanalimab & AB308 along with etrumadenant & quemliclustat & will hold exclusive rights outside the US
- Arcus to receive $725M as option fees along with royalties & the transaction is expected to close at the end of 2021. Both companies will co-develop & co-commercialize and share profits in the US related to these programs
- The companies will accelerate the clinical development of the clinical-stage products and facilitate the investigation of treatment combinations across the portfolios. Gilead will be able to add its portfolio products to existing Arcus studies
Click here to read full press release/ article | Ref: Gilead | Image: Gilead
The post Gilead Exercises its Options with Arcus for its Three Clinical-Stage Programs to Treat Cancers first appeared on PharmaShots.
